Product Images Zirabev

This is a chart showing the proportion of patients surviving after treatment with different medications for an unknown condition. The medications are referred to as IFL+ Placabo and IFL+ bevacizumab. The chart also displays the number of patients who received each treatment, as well as the duration of survival in months.*

This appears to be a table with data on survival rates in a medical study involving chemotherapy and the drug bevacizumab. The table contains information on the number of patients surviving in each month of the study, broken down by treatment group (chemotherapy alone or chemotherapy + bevacizumab). It is unclear what the units of measurement are for the "Proportion Surviving" column, and there is no additional context provided to interpret the findings.*

The text appears to be a table illustrating the proportion of overall survival between two groups, one group that received chemotherapy alone (n=225), and another group that received chemotherapy along with bevacizumab (n=227). The table shows the overall survival in months and the number of individuals at risk at different time intervals.*

Zirabev is an injection used for intravenous infusion after dilution that comes in a single-dose vial containing 100 mg/4 mL (25 mg/mL) of bevaczumab-bvr. The product should be stored at 2-8°C (6°F to &°F) and discarded after use. The solution contains a preservative, disodium edetate, polysorbate 80, succinic acid, sucrose, and water for injection. Dosage and administration must be done by a medical professional.*

This is a product label for the drug bevacizumab-bvzr, with dosage and administration instructions for intravenous infusion after dilution. It is supplied in a single-dose vial containing 400mg/16 mL, to be stored refrigerated at 2°C to 8°C in the original carton, protected from light. The drug is manufactured by Pfizer Inc. No further information is available.*

The text is a description of a pharmaceutical product called Zirabev, which is for intravenous infusion and contains bevacizumab-bvzr. The product comes in a single-dose vial and should be discarded if unused. It is stored in a carton between 2 and 8 degrees Celsius. The text also provides information on the contents of each carton, indicating that it contains a preservative-free solution of bevacizumab-bvzr at a concentration of 40mg/25mL and instructions on how to handle the product.*